Openbookopenbook
Equity
Eko International Cp(EKNL)
USD --+0.00%
Reward31Low
Risk64Medium-High
📊75%Data
EKNL
+0.0 · +0.00%
USD · PINK
Eko International Cp | Industrials
Capital Destroyer
Market Cap:316
ℹ️
Reward Rating
31
Low
Bottom 1% (model universe)
75% data coverage
ℹ️
Risk Rating
64
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on EKNL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Eko International Cp?

, through its joint venture interest in NeuroVasc Clinical Inc.

EKNL · Verdict

Limited reward · elevated risk

EKNL's standout is balance sheet; cash flow and profitability weigh on the picture.

Based on 88% data coverage

EKNL · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet68/100

    Current ratio 0.48

Watchouts 4

  • Cash flow5/100

    Weak vs peers

  • Profitability10/100

    0% return on equity

  • Growth18/100

    Earnings -56.3% CAGR

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Eko International Cp?

, through its joint venture interest in NeuroVasc Clinical Inc. , promotes and distributes frequency rhythmic electrical modulation system equipment used in the treatment of peripheral neuropathy in Canada. The company is listed on the PINK in USA, operating in the Industrials sector, with a market capitalisation of 316.00.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Performance tied to macro conditions — sensitive to interest rate cycles.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (31)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorIndustrials
Market Cap316.00
P/E RatioN/A
Dividend YieldN/A
52 Week HighN/A
52 Week LowN/A
Last AnnualJune
IPO DateN/A
IncorporatedUSA
Shares Outstanding32M
No. of EmployeesN/A
IndustryConglomerates
ExchangePINK
Beta1.46
CurrencyUSD
WebsiteN/A
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.